Trial Profile
An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 26 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Sep 2014 New trial record